The µ‐Opioid Receptor in Cancer and Its Role in Perineural Invasion: A Short Review and New Evidence
Source abstract
Abstract
Abstract Cancer is a significant public health problem worldwide. While there has been a steady decrease in the cancer death rate over the last two decades, the number of survivors has increased and, thus, cancer‐related sequela. Pain affects the life of patients with cancer and survivors. Prescription opioids continue as the analgesic of choice to treat moderate‐to‐severe cancer‐related pain. There has been controversy on whether opioids impact cancer progression by acting on cancer cells or the tumor microenvironment. The μ‐opioid receptor is the site of action of prescription opioids. This receptor can participate in an important mechanism of cancer spread, such as perineural invasion. In this review, current evidence on the role of the μ‐opioid receptor in cancer growth is summarized and preliminary evidence about its effect on the cross‐talk between sensory neurons and malignant cells is provided.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Cancer, Stress, Anesthesia, and Immune Response · Neuropeptides and Animal Physiology · Pain Management and Opioid Use
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Anesthesiology and Perioperative Medicine The University of Texas—MD Anderson Cancer Center Houston TX 77030 USA
Anesthesiology and Surgical Oncology Research Group Houston TX 77030 USA
Department of Pain Medicine The University of Texas—MD Anderson Cancer Center Houston TX 77030 USA
Department of Investigational Cancer Therapeutics The University of Texas—MD Anderson Cancer Center Houston TX 77030 USA
Rice University Houston TX 77005 USA
References (100+)
Show source-provided references
1. 10.1002/cncr.3358710.1002/cncr.33587 ↗
2. 10.3322/caac.2166010.3322/caac.21660 ↗
3. American Cancer Society
4. 10.1093/annonc/mdm05610.1093/annonc/mdm056 ↗
5. 10.1097/PR9.000000000000081010.1097/PR9.0000000000000810 ↗
6. 10.1016/j.pain.2010.09.00410.1016/j.pain.2010.09.004 ↗
7. 10.6004/jnccn.2021.702610.6004/jnccn.2021.7026 ↗
8. 10.1016/S1098-3597(05)80003-110.1016/S1098-3597(05)80003-1 ↗
9. 10.1001/jamaoncol.2018.157410.1001/jamaoncol.2018.1574 ↗
10. 10.1093/pm/pnz24210.1093/pm/pnz242 ↗
11. 10.1177/019459981880851310.1177/0194599818808513 ↗
12. 10.1002/pon.491710.1002/pon.4917 ↗
13. 10.1002/ejp.149410.1002/ejp.1494 ↗
14. Gorur A. · Life Sci. · 2021 · 278
15. 10.1371/journal.pone.009157710.1371/journal.pone.0091577 ↗
16. 10.1007/s00280-019-03816-310.1007/s00280-019-03816-3 ↗
17. 10.1213/ANE.0b013e318232b35a10.1213/ANE.0b013e318232b35a ↗
18. Gupta K. · Cancer Res. · 2002 · 62 · 4491
19. 10.4161/cc.2849310.4161/cc.28493 ↗
20. 10.18632/oncotarget.95210.18632/oncotarget.952 ↗
21. 10.4149/endo_2009_01_2310.4149/endo_2009_01_23 ↗
22. 10.3390/cancers1201013410.3390/cancers12010134 ↗
23. 10.3389/fonc.2021.68687710.3389/fonc.2021.686877 ↗
24. 10.1016/j.bja.2020.07.05110.1016/j.bja.2020.07.051 ↗
25. 10.1111/dote.1216510.1111/dote.12165 ↗
26. 10.1097/ALN.0b013e31824babe210.1097/ALN.0b013e31824babe2 ↗
27. 10.1002/cncr.2834510.1002/cncr.28345 ↗
28. 10.1111/cts.1224610.1111/cts.12246 ↗
29. 10.1126/science.179.4077.101110.1126/science.179.4077.1011 ↗
30. 10.1073/pnas.70.7.194710.1073/pnas.70.7.1947 ↗
31. 10.1111/j.1471-4159.2008.05833.x10.1111/j.1471-4159.2008.05833.x ↗
32. 10.2217/pgs.11.6810.2217/pgs.11.68 ↗
33. 10.1146/annurev-med-062613-09310010.1146/annurev-med-062613-093100 ↗
34. 10.36076/ppj.2008/11/S13310.36076/ppj.2008/11/S133 ↗
35. 10.1016/j.ejphar.2016.07.02810.1016/j.ejphar.2016.07.028 ↗
36. Opioids inLiverTox: Clinical and Research Information on Drug‐Induced Liver Injury Bethesda MD2012.
37. 10.1074/jbc.270.51.3029010.1074/jbc.270.51.30290 ↗
38. 10.1124/pr.112.00713810.1124/pr.112.007138 ↗
39. 10.1208/s12248-008-9056-110.1208/s12248-008-9056-1 ↗
40. 10.1097/ALN.000000000000096310.1097/ALN.0000000000000963 ↗
41. 10.1016/j.npep.2005.07.00110.1016/j.npep.2005.07.001 ↗
42. Vassou D. · Int. J. Oncol. · 2011 · 39 · 697
43. 10.3389/fphar.2018.0138810.3389/fphar.2018.01388 ↗
44. 10.1191/0269216306pm1124oa10.1191/0269216306pm1124oa ↗
45. 10.1097/00000542-199509000-0000810.1097/00000542-199509000-00008 ↗
46. Hernandez M. C. · J. Pharmacol. Exp. Ther. · 1993 · 267 · 133610.1016/S0022-3565(25)39585-6 ↗
47. 10.2353/ajpath.2010.09045710.2353/ajpath.2010.090457 ↗
48. 10.1159/00050210710.1159/000502107 ↗
49. Bimonte S. · Biomed. Res. Int. · 2015 · 2015
50. 10.2353/ajpath.2010.09062110.2353/ajpath.2010.090621 ↗
51. 10.1016/j.ajpath.2013.12.01910.1016/j.ajpath.2013.12.019 ↗
52. 10.1152/ajpcell.00443.201810.1152/ajpcell.00443.2018 ↗
53. 10.1093/abbs/gmx13110.1093/abbs/gmx131 ↗
54. 10.1016/j.yexcr.2009.04.00210.1016/j.yexcr.2009.04.002 ↗
55. 10.1093/bja/aer25910.1093/bja/aer259 ↗
56. 10.1080/0886022X.2016.125632210.1080/0886022X.2016.1256322 ↗
57. 10.18632/oncotarget.289410.18632/oncotarget.2894 ↗
58. 10.1038/labinvest.2016.10910.1038/labinvest.2016.109 ↗
59. 10.1002/jcp.3042110.1002/jcp.30421 ↗
60. 10.3389/fonc.2021.66644610.3389/fonc.2021.666446 ↗
61. 10.1016/S0014-2999(97)01213-210.1016/S0014-2999(97)01213-2 ↗
62. 10.5114/ceji.2014.4593910.5114/ceji.2014.45939 ↗
63. 10.3892/or.2013.264010.3892/or.2013.2640 ↗
64. 10.1152/ajpregu.00646.200910.1152/ajpregu.00646.2009 ↗
65. 10.1016/j.bja.2020.07.05110.1016/j.bja.2020.07.051 ↗
66. Lahav Y. · J. Voice · 2021 · 0892 · 00088
67. 10.1038/s41598-021-84787-510.1038/s41598-021-84787-5 ↗
68. 10.1093/annonc/mdw31710.1093/annonc/mdw317 ↗
69. 10.1016/j.bja.2021.03.03010.1016/j.bja.2021.03.030 ↗
70. 10.1016/j.jclinane.2015.07.01210.1016/j.jclinane.2015.07.012 ↗
71. 10.1097/j.pain.000000000000163010.1097/j.pain.0000000000001630 ↗
72. 10.1002/cam4.23610.1002/cam4.236 ↗
73. 10.1001/archoto.2009.10710.1001/archoto.2009.107 ↗
74. 10.1093/bja/aeu35110.1093/bja/aeu351 ↗
75. 10.1007/s00228-019-02801-210.1007/s00228-019-02801-2 ↗
76. 10.3332/ecancer.2020.112110.3332/ecancer.2020.1121 ↗
77. 10.1002/cncr.2439610.1002/cncr.24396 ↗
78. 10.1038/nrc.2016.3810.1038/nrc.2016.38 ↗
79. Chen S. H. · Am. J. Cancer Res. · 2019 · 9 · 1
80. Deng J. · PLoS One · 2014 · 9
81. 10.21873/anticanres.1428310.21873/anticanres.14283 ↗
82. 10.1186/1756-9966-29-2410.1186/1756-9966-29-24 ↗
83. 10.1016/j.ijrobp.2018.12.00910.1016/j.ijrobp.2018.12.009 ↗
84. 10.1016/j.hpb.2019.11.01010.1016/j.hpb.2019.11.010 ↗
85. 10.1038/nrc313110.1038/nrc3131 ↗
86. 10.1371/journal.pone.006052910.1371/journal.pone.0060529 ↗
87. 10.21873/anticanres.1413310.21873/anticanres.14133 ↗
88. 10.3389/fphar.2013.0012310.3389/fphar.2013.00123 ↗
89. 10.1016/j.bja.2020.03.03410.1016/j.bja.2020.03.034 ↗
90. 10.2147/JPR.S19190010.2147/JPR.S191900 ↗
91. 10.1073/pnas.210331911810.1073/pnas.2103319118 ↗
92. 10.3390/ijms2301014010.3390/ijms23010140 ↗
93. 10.3389/fpsyt.2018.0025710.3389/fpsyt.2018.00257 ↗
94. 10.1093/cercor/bhj14210.1093/cercor/bhj142 ↗
95. 10.1016/j.brainresbull.2015.12.00510.1016/j.brainresbull.2015.12.005 ↗
96. 10.1126/science.753136710.1126/science.7531367 ↗
97. 10.1177/15353702052300040710.1177/153537020523000407 ↗
98. 10.1158/1541-7786.MCR-12-060910.1158/1541-7786.MCR-12-0609 ↗
99. 10.1097/MPA.000000000000109010.1097/MPA.0000000000001090 ↗
100. 10.1016/j.neuroscience.2018.01.04810.1016/j.neuroscience.2018.01.048 ↗